

Figure S1




Figure S2




Figure S3









Figure S4

control
 5 μ M mifepristone
 50 μ M mifepristone
 100 μ M mifepristone

Supplemental table S1. Baseline characteristics of women contributing to paired breast biopsies, before and after mifepristone treatment, expressed as median (range).

| | |
|-------------------------|--------------------|
| Age (years) | 33 (21 – 41) |
| Pregnancies | 1.5 (0 – 5) |
| Parity | 2 (0 – 3) |
| Cycle length (days) | 29 (27 – 32) |
| Menstrual period (days) | 5 (3 – 7) |
| Body Mass Index | 25.8 (18.4 – 32.0) |

Supplemental table S2. Top 10 enriched pathways of the upregulated differently expressed genes as determined by Reactome pathway analysis.

| Pathway ID | Name | FDR (Padj) | Genes |
|---------------|---|------------|--|
| R-HSA-1474228 | Degradation of the extracellular matrix | 1.80E-09 | CTSG. TPSAB1. COL1A1. COL1A2. COL3A1. COL5A1. MMP2 |
| R-HSA-1474244 | Extracellular matrix organization | 2.57E-09 | CTSG. TPSAB1. COL1A1. COL1A2. COL3A1. ADAMTS2. COL5A1. MMP2 |
| R-HSA-1650814 | Collagen biosynthesis and modifying enzymes | 9.22E-08 | COL1A1. COL1A2. COL3A1. ADAMTS2. COL5A1 |
| R-HSA-1442490 | Collagen degradation | 9.22E-08 | COL1A1. COL1A2. COL3A1. COL5A1. MMP2 |
| R-HSA-3000170 | Syndecan interactions | 1.76E-07 | COL1A1. COL1A2. COL3A1. COL5A1 |
| R-HSA-1474290 | Collagen formation | 2.30E-07 | COL1A1. COL1A2. COL3A1. ADAMTS2. COL5A1 |
| R-HSA-8874081 | MET activates PTK2 signaling | 2.30E-07 | COL1A1. COL1A2. COL3A1. COL5A1 |
| R-HSA-8875878 | MET promotes cell motility | 6.69E-07 | COL1A1. COL1A2. COL3A1. COL5A1 |
| R-HSA-8948216 | Collagen chain trimerization | 8.81E-07 | COL1A1. COL1A2. COL3A1. COL5A1 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 2.460x10-6 | COL1A1. COL1A2. COL3A1. COL5A1 |

FDR=false discovery rate